What You Should Know
- CareDx has entered into a definitive agreement to acquire Naveris, a precision oncology company specializing in blood-based monitoring for viral-mediated cancers.
- The deal includes $160M in up-front cash, with potential for an additional $100M based on future revenue milestones.
- Naveris’ flagship platform utilizes Tumor Tissue Modified Viral (TTMV®) DNA to detect and monitor HPV-driven cancers with high accuracy.
- The acquisition is expected to close in the third quarter of 2026, subject to customary closing conditions.
- Naveris reported unaudited revenue of $34M in 2025, with a projected annual growth rate of 30-40% over the next three years.
CareDx, traditionally a leader in the transplant diagnostics space, has made a significant move to diversify its portfolio by acquiring Naveris, a commercial-stage precision oncology firm. This $260 million deal marks a major expansion of CareDx’s U.S. Precision Medicine Testing Services, moving beyond organ health into the high-growth field of liquid biopsy for cancer surveillance.
The acquisition centers on Naveris’ proprietary NavDx® test, a clinically validated liquid biopsy that measures fragments of viral DNA released from tumor tissue. This “tumor-naïve” approach is particularly effective for human papillomavirus (HPV)-driven cancers, providing a non-invasive way to manage patients from initial diagnosis through post-treatment molecular residual disease (MRD) surveillance.
Leveraging Core Competencies in Specialty Markets
The acquisition of Naveris will enable CareDx to target concentrated specialty markets characterized by a high burden of disease and a requirement for repeat testing. This aligns with CareDx’s existing expertise in navigating complex clinical workflows and generating the evidence necessary for robust insurance coverage and reimbursement.
Naveris has already seen strong commercial traction, having performed over 130,000 tests to date. Its solutions are already leading the market in Head & Neck and Anal cancer MRD surveillance. John Hanna, President & CEO of CareDx, noted that the acquisition allows the company to apply its strengths in building belief in molecular testing to a technology that is still in the early stages of broad clinical adoption.
Financial Performance and Strategic Outlook
Financially, the deal adds a rapidly growing revenue stream to CareDx’s balance sheet. Naveris’ performance in the first quarter of 2026 showed approximately $12 million in revenue with strong gross margins of 65%. Despite a small net operating loss in Q1, CareDx expects the transaction will not impact its 2026 AEBITDA guidance.
The integration of Naveris’ 100 employees and its accredited high-complexity laboratories in Massachusetts and North Carolina will provide CareDx with the operational infrastructure to scale these oncology services nationwide. As the two companies combine forces, the focus will remain on improving patient outcomes by delivering disruptive technology that simplifies how viral-driven cancers are detected and managed.
Why This Matters
As HPV-mediated cancers continue to increase in incidence, the ability to detect recurrence earlier and more accurately than conventional imaging will become the standard of care. CareDx isn’t just buying a test; it’s buying a dominant position in the next generation of cancer survivorship.
